Home Contact COMPANY Forendo Pharma is a drug discovery and development company with core competence in tissue specific regulation of sex hormone effects. Its two first-in-class product candidates are progressing to offer significant therapeutic benefits in men´s and women´s health FISPEMIFENE Fispemifene is the first selective estrogen receptor modulator designed only for men. It will be developed for treatment of symptoms of low testosterone. In phase II clinical studies in men with secondary hypogonadism, fispemifene has effectively normalized the low testosterone levels. HSD 17HSD1-inhibitor is progressing into clinical development with a focus on endometriosis. The potent and selective lead compounds have demonstrated in vivo proof of efficacy in disease model of endometriosis. This “first-in-man” mechanism offers potentially multiple benefits over the current endometriosis therapies. <a href="http://meltwaternews.com/magenta/xml/html/14/84/1/v2_437209.html">Press Clipping Service</a> “Growth in Sight” prize awarded to Forendo Pharma June 16, 2015 • Pasi Koskimies